Cyclin-Dependent Kinases
Cyclin-dependent kinases is a group of serine/threonine kinases. It is activated by binding to cyclin and participates in the regulation of cell cycle.
Products Related to Cyclin-Dependent Kinases(70)
- GC17648Dinaciclib(SCH727965)CAS: 779353-01-4Purity: >98.00%
Dinaciclib(SCH727965) (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.
- GC11396SNS-032 (BMS-387032)CAS: 345627-80-7Purity: >99.00%
SNS-032 (BMS-387032) (BMS-387032) is a potent and selective inhibitor ofCDK2, CDK7, and CDK9 withIC50sof 38 nM, 62 nM and 4 nM, respectively. SNS-032 (BMS-387032) has antitumor effect.
- GC11401Roscovitine (Seliciclib,CYC202)CAS: 186692-46-6Purity: >98.00%
Roscovitine (Seliciclib,CYC202) is an effective inhibitor of Cdk2/cyclin E with an IC 50 value of 0.1μM. Roscovitine also inhibits Cdk7/cyclin H, Cdk5/p35, and (cdc)/cyclin B, with IC 50 values of 0.49, 0.16, and 0.65μM, respectively.
- GC11564Cdk4/6 Inhibitor IVCAS: 359886-84-3Purity: >99.50%
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer.
- GC11823LY2835219 free baseCAS: 1231929-97-7Purity: >99.00%
LY2835219 free base is a potent and selective inhibitor of CDK4 and CDK6 with IC 50 of 2nM and 10nM in cell-free assays, respectively.
- GC11835DeferasiroxCAS: 201530-41-8Purity: >99.50%
Deferasirox is an orally active iron chelator used to treat iron overload diseases.
- GC13100[Ala92]-p16 (84-103)CAS: 189064-08-2Purity: >98%
inhibitor of cyclin-dependent kinase-4 (cdk4)/cyclin D1
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC10840 | THZ1 | 1604810-83-4 | >98.50% | |
Covalent CDK7 inhibitor,potent and selective | ||||
| GC10842 | LEE011 | 1211441-98-3 | >99.50% | |
LEE011 is an ATP-competitive and orally active CDK4/6 inhibitor with IC50 values of 10nM and 39nM. | ||||
| GC12438 | AZD-5438 | 602306-29-6 | >99.50% | |
Potent CDK1/2/9 inhibitor | ||||
| GC17648 | Dinaciclib(SCH727965) | 779353-01-4 | >98.00% | |
Dinaciclib(SCH727965) (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively. | ||||
| GC11396 | SNS-032 (BMS-387032) | 345627-80-7 | >99.00% | |
SNS-032 (BMS-387032) (BMS-387032) is a potent and selective inhibitor ofCDK2, CDK7, and CDK9 withIC50sof 38 nM, 62 nM and 4 nM, respectively. SNS-032 (BMS-387032) has antitumor effect. | ||||
| GC11401 | Roscovitine (Seliciclib,CYC202) | 186692-46-6 | >98.00% | |
Roscovitine (Seliciclib,CYC202) is an effective inhibitor of Cdk2/cyclin E with an IC 50 value of 0.1μM. Roscovitine also inhibits Cdk7/cyclin H, Cdk5/p35, and (cdc)/cyclin B, with IC 50 values of 0.49, 0.16, and 0.65μM, respectively. | ||||
| GC11410 | Aminopurvalanol A | 220792-57-4 | >98% | |
cyclin-dependent kinase inhibitor | ||||
| GC11564 | Cdk4/6 Inhibitor IV | 359886-84-3 | >99.50% | |
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer. | ||||
| GC11634 | NSC 693868 | 40254-90-8 | >98% | |
CDKs and GSK-3 inhibitor | ||||
| GC11785 | CDK4 inhibitor | 1256963-02-6 | >98% | |
CDK4/Cyclin D1 inhibitor | ||||
| GC11823 | LY2835219 free base | 1231929-97-7 | >99.00% | |
LY2835219 free base is a potent and selective inhibitor of CDK4 and CDK6 with IC 50 of 2nM and 10nM in cell-free assays, respectively. | ||||
| GC11835 | Deferasirox | 201530-41-8 | >99.50% | |
Deferasirox is an orally active iron chelator used to treat iron overload diseases. | ||||
| GC11944 | PF 4800567 hydrochloride | 1391052-28-0 | >98% | |
casein kinase 1ε inhibitor | ||||
| GC11971 | LY2857785 | 1619903-54-6 | >98.50% | |
CDK9 inhibitor | ||||
| GC12001 | BS-181 | 1092443-52-1 | >98% | |
A selective Cdk7 inhibitor | ||||
| GC12064 | SB1317 | 937270-47-8 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC12348 | Ro 3306 | 872573-93-8 | >98.00% | |
Ro 3306 functions as the ATP-competitive inhibitor targeting CDK1/cyclin B1 with K i value of 35nmol/L, and targeting CDK1/cyclin A complexes with K i value of 110nmol/L. | ||||
| GC12425 | CDK inhibitor II | 1269815-17-9 | >98.50% | |
| GC12826 | AZD-5597 | 924641-59-8 | >98% | |
Potent CDK inhibitor | ||||
| GC12865 | BMS265246 | 582315-72-8 | >99.00% | |
CDK1/2 inhibitor,potent and selective | ||||
| GC12871 | CDK9 inhibitor | 1415559-43-1 | >98.50% | |
| GC12886 | NSC 625987 | 141992-47-4 | >98% | |
Cyclin-dependent kinase (cdk) 4 inhibitor | ||||
| GC13100 | [Ala92]-p16 (84-103) | 189064-08-2 | >98% | |
inhibitor of cyclin-dependent kinase-4 (cdk4)/cyclin D1 | ||||
| GC13511 | THZ2 | 1604810-84-5 | >99.50% | |
CDK7 inhibitor | ||||
